Objectives
Primary Objective
The primary objective of the CONVINCE study is to compare high-dose haemodiafiltration with high-flux haemodialysis treatment in terms of all-cause mortality.
Primary Endpoint
The primary endpoint is defined as difference in rate for all-cause mortality.
Secondary Objectives
- Compare high-dose high-dose haemodiafiltration with high-flux haemodialysis treatment in terms of cause specific morbidity and mortality.
- Assess patient reported outcome measures and patient reported experience measures to capture and patient perspectives and compare between high-dose haemodiafiltration with high-flux haemodialysis treatment.
3. Assess cost effectiveness of high-dose haemodiafiltration compared to high-flux haemodialysis.
Secondary Endpoints
The secondary endpoints are:
- Cause specific mortality (at least cardiovascular and non-cardiovascular death; others with high frequency may be added);
- Non-fatal and fatal cardiovascular events;
- Hospitalisation for infection-related conditions;
- All cause hospitalisations;
- PREMS and PROMS;
6. Cost effectiveness.
![Image of Eudial logo Image of Eudial logo](https://www.ucl.ac.uk/convince-hemodiafiltration-dialysis-study/sites/convince_hemodiafiltration_dialysis_study/files/styles/small_image/public/eudial2_5.jpg?itok=dgneksVU)
![Eufalg](https://www.ucl.ac.uk/convince-hemodiafiltration-dialysis-study/sites/convince_hemodiafiltration_dialysis_study/files/styles/non_responsive/public/euflag_3.png?itok=pTJxVa1m)